<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177746</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-10.16</org_study_id>
    <nct_id>NCT03177746</nct_id>
  </id_info>
  <brief_title>The Safety of Dapoxetine/Tadalafil Combination Therapy</brief_title>
  <official_title>The Safety of Dapoxetine/Tadalafil Combination Therapy in Treatment of Men With Premature Ejaculation and Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Dapoxetine/Tadalafil
      30/20 mg film-coated tablet in the treatment of men with premature ejaculation and erectile
      dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Anticipated">February 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety of study drug</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Intra-vaginal ejaculation latency time difference of one minute or more will be considered as efficient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of IIEF-15 (International Index of Erectile Function) score compared to baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Increase in IIEF score will be considered as efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of premature ejaculation symptom scores compared to baseline</measure>
    <time_frame>4 weeks</time_frame>
    <description>Increase in IIEF scores will be considered as efficacy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Premature Ejaculation</condition>
  <condition>Erectile Dysfunction</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Dapoxetine/Tadalafil 30/20 mg film coated tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapoxetine/Tadalafil 30/20 mg film coated tablet</intervention_name>
    <description>During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.
Study drug should not be used more than 1 tablet every 24 hours during the treatment.</description>
    <arm_group_label>Dapoxetine/Tadalafil 30/20 mg film coated tablet</arm_group_label>
    <other_name>Tada Plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-64 years old men,

          -  Participants must be heterosexual males and in a stable monogamous sexual relationship
             with a female partner for at least 6 months and will continue throughout the study,

          -  Clinical diagnosis of erectile dysfunction, IIEF score ≤21,

          -  Premature Ejaculation Diagnostic Tool (PEDT) score must be ≥11

          -  Patients with life-long PE and acquired PE according to the description of
             International Society for Sexual Medicine (ISSM) ,

          -  The patient and his partner must have sexual intercourse twice a week for the duration
             of the study,

          -  Commitment to comply with the study protocol,

          -  Patients who sign informed consent form (ICF).

        Exclusion Criteria:

          -  History of medical events such as surgical interventions or neurologic conditions
             (e.g., multiple sclerosis), trauma, or infections that are associated with the
             development of symptoms of premature ejaculation (PE) and considered a potential cause
             of PE,

          -  Having genital abnormalities, except penile curvature unless not prevent sexual
             intercourse,

          -  Developed erectile dysfunction or premature ejaculation due to drug use or quit taking
             drugs,

          -  Any conditions that prevent sexual intercourse with partners

          -  History of epilepsy,

          -  Severe renal insufficiency,

          -  Liver disease,

          -  History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New
             York Cardiovascular Associates (NYCA) phase II-IV), atrioventricular block or message
             disorder such as sick sinus syndrome, severe ischemic cardiac disease, syncope,
             unstable angina, life-threatening arrhythmia or hypotension,

          -  Non-Arteritic Anterior ischemic optic neuropathy,

          -  Patients who are not eligible to have sexual intercourse due to existing health
             problems,

          -  Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer,
             abnormalities in ECG, severe systemic disease that cannot be controlled,

          -  Systolic/Diastolic blood pressure at rest &lt;90/50 mmHg and 170/100 mmHg&lt;

          -  History of allergy to Selective Serotonin Reuptake Inhibitor (SSRI) and
             phosphodiesterase inhibitor drugs,

          -  Continuing to use or quitted in last 3 months of Monoamine oxidase inhibitor (MAOI),
             Thioridazine, Serotonin Reuptake Inhibitor (SSRI), Selective-norepinephrine Reuptake
             Inhibitor (SNRI), Serotonergic drug/herbal product, tricyclic antidepressant and
             atypical antipsychotic drugs,

          -  Use of nitrates, alfa blockers, vasodilators, ketoconazole, itraconazole, ritonavir,
             saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, cimetidine,
             erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant,
             verapamil, diltiazem, any kind of vasodilator, antiplatelet, anticoagulant,
             dapoxetine, phosphodiesterase 5 inhibitor, alcohol and stimulant drug,

          -  Patients on a different therapy (behavioral therapy or other drugs that are applied
             locally) for PE treatment

          -  During the study, the possibility of taking medication which may affect the study
             drug's pharmacokinetic/pharmacodynamic properties

          -  Patients who are defining symptoms of prostatitis clinically

          -  Thyroid hormone disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Since drug is indicated in men, study population will consist of men.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Okmeydanı Training and Research Hospital Urology Dep.</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

